Human Influenza Clinical Trial
Official title:
Safety and Immunogenicity of Influenza Vaccine Among HIV-infected Young Subjects: Conventional Vaccine Versus Intradermal Vaccine
Several studies have shown poor immune response to conventional influenza vaccines in HIV-infected individuals. This study was conducted expecting the more potent immunogenicity of intradermal vaccine compared with conventional intramuscular vaccine in HIV-infected adults.
During the 2011/2012 pre-influenza season, three vaccines were used in HIV-infected adults (18 to 60 years): inactivated intramuscular vaccine (Agripal), reduced-content intradermal vaccine (IDflu9μg) and standard-content intradermal vaccine (IDflu15μg). Serum hemagglutination-inhibiting (HI) antibodies and INF-γ ELISpot assay were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded for 7 days. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01690637 -
Panama and El Salvador Children's Oseltamivir Study
|
Phase 4 | |
| Completed |
NCT03572491 -
Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine
|
Phase 3 | |
| Recruiting |
NCT04487041 -
Tfh Dysfunction in HIV and Aging
|
Phase 4 | |
| Completed |
NCT02387294 -
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
|
Phase 3 | |
| Completed |
NCT02600585 -
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults
|
N/A | |
| Completed |
NCT01511744 -
Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine
|
Phase 4 | |
| Completed |
NCT01342796 -
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
|
Phase 2 | |
| Completed |
NCT01677702 -
Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization
|
N/A | |
| Active, not recruiting |
NCT01096225 -
Immunogenicity Study of S-OIV H1N1 Influenza Vaccine
|
N/A | |
| Completed |
NCT00880659 -
Bangladesh Secondary Transmission Handwashing Protocol
|
Phase 2 | |
| Completed |
NCT01879540 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
|
Phase 2 | |
| Completed |
NCT01879553 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
|
Phase 2 | |
| Completed |
NCT01636102 -
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
|
Phase 2 | |
| Completed |
NCT01651104 -
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
|
Phase 2 | |
| Completed |
NCT03448705 -
Safety of 4Fluart ID Suspension for Injection in Adult Subjects
|
Phase 1 | |
| Completed |
NCT02478905 -
Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting
|
N/A | |
| Recruiting |
NCT04431050 -
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
|
||
| Completed |
NCT01568788 -
Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine
|
N/A | |
| Completed |
NCT05155319 -
Universal Influenza A Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01880697 -
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
|
Phase 3 |